FDA Approves Inclisiran

Today the FDA announced the approval of inclisiran (Leqvio) as a treatment for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional low-density lipoprotein cholesterol (LDL-C) lowering. Inclisiran is an injection administered in the doctor’s office twice a year to be used along with diet and maximally tolerated statin therapy and may reduce circulating levels of LDL-C up to 51%.